bluebird bio, Inc. (BLUE)
NASDAQ: BLUE · Real-Time Price · USD
8.35
+0.09 (1.09%)
Jan 17, 2025, 4:00 PM EST - Market closed
bluebird bio Revenue
bluebird bio had revenue of $10.61M in the quarter ending September 30, 2024, a decrease of -14.36%. This brings the company's revenue in the last twelve months to $53.12M, up 144.50% year-over-year. In the year 2023, bluebird bio had annual revenue of $29.50M with 720.04% growth.
Revenue (ttm)
$53.12M
Revenue Growth
+144.50%
P/S Ratio
1.37
Revenue / Employee
$141,653
Employees
375
Market Cap
81.18M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
BLUE News
- 6 weeks ago - bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition - Business Wire
- 6 weeks ago - Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels - Business Wire
- 6 weeks ago - bluebird bio Announces 1-for-20 Reverse Stock Split - Business Wire
- 6 weeks ago - bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model - Business Wire
- 7 weeks ago - FDA investigates risk of blood cancers from bluebird bio's gene therapy - Reuters
- 2 months ago - My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys - Seeking Alpha
- 2 months ago - JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options - Benzinga
- 2 months ago - bluebird bio, Inc. (BLUE) Q3 2024 Earnings Call Transcript - Seeking Alpha